EP0675723A4 - Therapie utilisant des bisphosphonates et des strogenes en vue de traiter et de prevenir la resorption osseuse. - Google Patents

Therapie utilisant des bisphosphonates et des strogenes en vue de traiter et de prevenir la resorption osseuse.

Info

Publication number
EP0675723A4
EP0675723A4 EP94905419A EP94905419A EP0675723A4 EP 0675723 A4 EP0675723 A4 EP 0675723A4 EP 94905419 A EP94905419 A EP 94905419A EP 94905419 A EP94905419 A EP 94905419A EP 0675723 A4 EP0675723 A4 EP 0675723A4
Authority
EP
European Patent Office
Prior art keywords
biphosphonate
treating
bone loss
preventing bone
estrogen therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP94905419A
Other languages
German (de)
English (en)
Other versions
EP0675723A1 (fr
Inventor
Donna T Whiteford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0675723A1 publication Critical patent/EP0675723A1/fr
Publication of EP0675723A4 publication Critical patent/EP0675723A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP94905419A 1992-12-23 1993-12-17 Therapie utilisant des bisphosphonates et des strogenes en vue de traiter et de prevenir la resorption osseuse. Ceased EP0675723A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99641892A 1992-12-23 1992-12-23
PCT/US1993/012302 WO1994014455A1 (fr) 1992-12-23 1993-12-17 Therapie utilisant des bisphosphonates et des ×strogenes en vue de traiter et de prevenir la resorption osseuse
US996418 1997-12-22

Publications (2)

Publication Number Publication Date
EP0675723A1 EP0675723A1 (fr) 1995-10-11
EP0675723A4 true EP0675723A4 (fr) 1998-08-05

Family

ID=25542895

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94905419A Ceased EP0675723A4 (fr) 1992-12-23 1993-12-17 Therapie utilisant des bisphosphonates et des strogenes en vue de traiter et de prevenir la resorption osseuse.

Country Status (5)

Country Link
EP (1) EP0675723A4 (fr)
JP (1) JPH08505142A (fr)
AU (1) AU5953894A (fr)
CA (1) CA2151240A1 (fr)
WO (1) WO1994014455A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9307859A (pt) * 1993-05-15 1996-01-09 Boehringer Mannheim Gmbh Comprimido com biodisponibilidade aperfeiçoada que contérn ácido
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
TW398975B (en) * 1994-07-22 2000-07-21 Lilly Co Eli Pharmaceutical composition for inhibiting bone loss
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
CA2219354A1 (fr) * 1995-05-12 1996-11-14 Merck & Co., Inc. Prevention des pertes de dnets par l'administration d'alendronate ou de ses sels
US5545635A (en) * 1995-05-23 1996-08-13 Eli Lilly And Company Inhibiting bone loss with equilenin
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
IL120265A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
JP2000511178A (ja) * 1996-05-17 2000-08-29 メルク エンド カンパニー インコーポレーテッド 発泡性ビスホスホネート製剤
EP1378234A1 (fr) * 1996-05-17 2004-01-07 MERCK & CO. INC. Formulation de bisphosphonate effervescente
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
EP0949928A4 (fr) * 1996-11-25 2000-09-13 Merck & Co Inc Agents androgene et bisphosphonique coadministres pour traiter des maladies
DE19719680A1 (de) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
US6555529B1 (en) * 1997-12-25 2003-04-29 Toray Industries, Inc. Remedies for intramedullary diseases
AU756540B2 (en) * 1998-12-04 2003-01-16 Roche Diagnostics Gmbh Use of ibandronate for promoting osseointegration of endoprostheses
WO2000064516A1 (fr) * 1999-04-22 2000-11-02 Hydromed Sciences A Division Of Gp Strategies Corporation Administration regulee de bisphosphonates
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
FR2803521B1 (fr) * 2000-01-12 2002-10-25 Ceva Sante Animale Utilisation de l'acide tiludronique et de ses derives chez la volaille pour la preparation d'un medicament destine a prevenir et a traiter l'osteoporose
PL361909A1 (en) * 2001-02-06 2004-10-04 The Royal Alexandra Hospital For Children A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
EP1383509A4 (fr) * 2001-04-03 2005-10-26 Royal Alexandra Hosp Children Medicament a utiliser en matiere de greffe osseuse
AUPR553701A0 (en) * 2001-06-07 2001-07-12 Royal Alexandra Hospital For Children, The A device for the delivery of a drug to a fractured bone
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
NZ552514A (en) 2001-12-24 2008-08-29 Teva Pharma Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
US7488496B2 (en) 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
ES2561463T3 (es) * 2003-08-21 2016-02-26 Addbio Ab Dispositivo de implante recubierto con bisfosfonato y método para el mismo
ES2379485T3 (es) 2005-10-27 2012-04-26 Thommen Medical Ag Implante dental y procedimiento para su fabricación
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005187A1 (fr) * 1990-09-18 1992-04-02 Boehringer Mannheim Gmbh NOUVEAUX DERIVES DE 17-β-OESTRADIOL, LEUR PROCEDE DE PRODUCTION ET MEDICAMENTS CONTENANT CES COMPOSES
EP0496520A1 (fr) * 1991-01-22 1992-07-29 Merck & Co. Inc. Agents actifs sur les os
WO1992014474A1 (fr) * 1991-02-26 1992-09-03 Norwich Eaton Pharmaceuticals, Inc. Procede de traitement de l'osteoporose

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005187A1 (fr) * 1990-09-18 1992-04-02 Boehringer Mannheim Gmbh NOUVEAUX DERIVES DE 17-β-OESTRADIOL, LEUR PROCEDE DE PRODUCTION ET MEDICAMENTS CONTENANT CES COMPOSES
EP0496520A1 (fr) * 1991-01-22 1992-07-29 Merck & Co. Inc. Agents actifs sur les os
WO1992014474A1 (fr) * 1991-02-26 1992-09-03 Norwich Eaton Pharmaceuticals, Inc. Procede de traitement de l'osteoporose

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CIMINERA N. ET AL: "Studio Comparativo degli effeti di estrogeni e difosfonati sulla perdita ossea postmenopausale", ANN. OSTET. GINECOL. MED. PERINAT., vol. 113, no. 5, 1992, pages 232 - 237, XP002064831 *
See also references of WO9414455A1 *

Also Published As

Publication number Publication date
JPH08505142A (ja) 1996-06-04
AU5953894A (en) 1994-07-19
CA2151240A1 (fr) 1994-07-07
EP0675723A1 (fr) 1995-10-11
WO1994014455A1 (fr) 1994-07-07

Similar Documents

Publication Publication Date Title
DE69739758D1 (de) Vakzine zur behandlung von lymphomen und leukämie
EP1079741A4 (fr) Attache pour tissu implantable et systeme permettant de traiter les affections de reflux gastro-oesophagien
DE69312624D1 (de) Vorrichtung zur unterscheidung von tachykardien und fibrillationen und zur entsprechenden behandlung
ATA11989A (de) Mittel zur vorbeugung gegen und behandlung von parodontopathien
DE69525473D1 (de) Vorrichtung zur behandlung von blutgefässen
DE69730604D1 (de) Oxadisäuren und verwandte verbindungen zur behandlung von hautstörungen
DE69524682D1 (de) Mittel zur Behandlung von Wunden
DE59410094D1 (de) Vorrichtung zur behandlung von biologischem gewebe und körperkonkrementen
EP0651633A4 (fr) Phosphopeptides pour le traitement du tartre dentaire.
DE69018457D1 (de) Gegenstände zur behandlung von periodontitis und knochendefekten.
DE69427869D1 (de) Botulinumtoxine zur behandlung von hyperhydrosis
ATA76995A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen
EP0709090A3 (fr) Compositions pour le traitement de tumeurs résistantes
DE69526684D1 (de) Begasungsrührwerk zur Behandlung von Metallschmelzen
DE69112480D1 (de) Verfahren und Vorrichtung zur Behandlung von medizinischen Abfallstoffen.
DE69318693D1 (de) Magnetischer Konditionierer zur Behandlung von Flüssigkeiten
DE69220051D1 (de) Vorrichtung zur Behandlung von Getreide
DE69817862D1 (de) Naringin und naringenin als mittel zur vorbeugung oder behandlung von leber-erkrankungen
DE69421196D1 (de) Vorrichtung zur behandlung von überbiss
DE69527140D1 (de) Wirkstoff zur prävention oder behandlung von osteoporose
DE69506019D1 (de) Vorrichtung zur Behandlung von Schmerz
DE69729004D1 (de) Photodynamische therapie zur behandlung von osteosrthritis
DE69727240D1 (de) Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv
DE59501606D1 (de) Vorrichtung zur behandlung von leiterplatten
ZA931778B (en) Method and composition for the treatment of osteoporosis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950724

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19980619

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 19981008

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20031106

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1009249

Country of ref document: HK